April 21, 2011: Life Sciences / Biotech

March 24, 2011

in BioTech & Life Science,Events

“Personalized Medicine – a new era of customized health care. Science fiction? Not anymore!”

On April 21, CVF will host an event focusing on leading-edge developments and the major forces driving the next major revolution in healthcare and life sciences—Personalized Medicine. “While the subsequent decade has seen many false starts and false hopes, the age of personalized medicine is upon us. There is an ever-increasing number of examples of drugs, diagnostics, and treatment decisions being guided by a patient’s unique circumstances and characteristics, including individual gene and protein configurations.” (PwC. December 2010)

Date: Thursday, April 21, 2011
Time: 6-8 pm
Venue: WESST Enterprise Center
609 Broadway Blvd. NE
Albuquerque, NM 87102
Directions: Map
Cost: $22.50 in advance (credit card payments); $25 at the door (cash and check only).
Advance sales end at midnight, Wednesday, April 20.

feedback

The format of this 90-minute expert roundtable is well suited to deal with this complicated subject. Each of our guest experts will engage in a conversational information exchange followed by an interactive, stimulating discussion period with local NM leaders and innovators followed by Q&A with the general audience.

The experts will focus their discussion on:

  • a macro overview of personalized health care and what it means for the decade ahead;
  • key market opportunities and the formidable challenges for the life science community, policymakers, patients and society;
  • key business challenges. For example, demand for scalable informatics solutions for genome sequencing analysis ; and
  • the need for action: new developments on a actionable personalized health care roadmap in collaboration with Clay Christensen, author/architect of disruptive innovation. The Personalized Health Care roadmap will be a catalyzing force in the transformation of health care delivery and approaches.

Frederick S. Lee MD, MPH – Chief Medical Officer, P4 Medicine Institute
Fred Lee is the Chief Medical Officer of the P4 Medicine Institute, a nonprofit innovation consortium dedicated to creating a predictive, preventive, personalized, & participatory future of healthcare. P4MI’s charter members are the Institute for Systems Biology, and the Ohio State University Medical Center. He has helped establish and grow the burgeoning field of personalized healthcare through his ability to merge perspectives from the life sciences, healthcare delivery, clinical informatics, and public health. Fred brings a unique and broad range of professional experiences to the task of creating healthcare of the future, having spent time as a practicing clinician, as a healthcare system executive, and as a technologist and industry executive. From the industry perspective, Fred led product strategy efforts for McKesson Corporation in its Provider Technologies division, focusing on enhancing electronic health records to support genomic & molecular medicine. He has also held leadership roles in General Electric Healthcare, leading product strategy for GE Healthcare Information Technologies in the United Kingdom while working on the UK’s National Health Service Connecting for Health program.

Fred has held executive leadership roles in health systems in the New York/Long Island area, as a Chief Operating Officer and as a Chief Medical Information Officer of a large ambulatory care network in New York. Fred’s clinical background is in general surgery and preventive medicine. He received a BS from the Massachusetts Institute of Technology in Life Sciences, an MD and residency training from the Stony Brook University School of Medicine, and a Masters in Public Health degree from the Mailman School of Public Health at Columbia University.
YouTube Video» | Whitepaper»

Kimball Thomson – Executive Director, The National Summit on Personalized Health Care
National Summit on Personalized Health Care’s Board of Directors is comprised of an impressive group of experts, inclusive of Clay Christensen, author/architect of disruptive innovation (Harvard Business School) and Michael O. Leavitt, Leavitt Partners (former HHS Secretary). Other board members include Mara Aspinall, On-Q-ity; Leroy (Lee) Hood, Institute for Systems Biology; Clay Marsh, Ohio State University; Ralph Snyderman, Proventys and Duke University; Risa Stack, Kleiner Perkins Caufield & Byers; Eric Topol, Scripps Institute. Kimball also is the president & CEO of the Next Phase family of companies, which includes Next Phase Communications, PR and marketing; Next Phase Advisors, strategy and organizational development; and Next Phase Publishing, publishing consulting. Kimball has more than 15 years experience in communications, marketing and business development strategy. Kimball graduated from the University of California at Berkeley and did his MBA work at BYU.
The Roadmap for Personalized Health Care»

Ken Prokuski – Vice President of Operations, Complete Genomics
Since January 2010 Mr. Prokuski has held the position of Vice President of Operations at Complete Genomics. From August 2009 to January 2010, Mr. Prokuski served as an independent consultant to the company. From October 1993 to January 2009, Mr. Prokuski served as Senior Director of Manufacturing Operations at Applied Biosystems, a life sciences company and a division of Life Technologies. From September 1992 to September 1993, Mr. Prokuski served as Material Manager at Arico Coating Technology, a thin film deposition equipment manufacturer. From September 1991 to September 1992, Mr. Prokuski served as Director of Materials at Toshiba America, Inc., an electronics company. From January 1990 to August 1991, Mr. Prokuski served as Operations Manager at Millipore Corporation, a life sciences company. Mr. Prokuski received a B.A. in Psychology from Northeastern Illinois University and an Executive M.B.A. from Golden Gate University.

Complete Genomics is a complete human genome sequencing company that has developed and commercialized an innovative DNA sequencing platform. The Complete Genomics Analysis Platform (CGA™ Platform) combines Complete Genomics’ proprietary human genome sequencing technology with our advanced informatics and data management software. We offer this innovative, end-to-end, outsourced solution as CGA™ Service, and provide customers with data that is immediately ready to be used for genome-based research. Additional information can be found in the Company Profile, at www.completegenomics.com, and in an article reprint from Genetics in Medicine.

New Mexico Thought Leaders Discuss New Mexico Impact
The event will include invited New Mexico thought leaders  to react to the information presented by the guest experts and connect “HOW” the information impacts New Mexico. Areas of debate and discussion may include: organizational strategies, new business models, innovative opportunities, the nations’ health care challenges, future areas of collaboration. New Mexico thought leaders include:

  • Beverly Cormier, VP Commercialization, Exagen Diagnostics
  • Colin Dykes, PhD, Chief Scientific Officer, Nano MR
  • Maggie Gunter, PhD President, Executive Director, Lovelace Clinic Foundation
  • Meghan Norvell, PhD, COO, Azano Pharmaceuticals Inc.
  • UNM: TBD

feedback

Share This Post!
  • Facebook
  • Twitter
  • LinkedIn
  • Google Bookmarks

Previous post:

Next post: